Virtual Library

Start Your Search

Ying Liu



Author of

  • +

    P08 - Early Stage/Localized Disease - Epidemiology (ID 117)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Early Stage/Localized Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P08.10 - Clinical Characteristics and Outcomes of Simultaneous Multiple Primary Lung Cancer with Same Pathological Types (ID 1679)

      00:00 - 00:00  |  Presenting Author(s): Ying Liu

      • Abstract
      • Slides

      Introduction

      Simultaneous multiple primary lung cancer (sMPLC) is detected increasingly nowadays and most are with same pathological types. However, the clinical characteristics and outcomes of sMPLC with same pathological types have not been well characterized.

      Methods

      All consecutive patients diagnosed as sMPLC with same pathological types according to Martini-Melamed and American College of Chest Physicians criteria from October 2012 to June 2019 were enrolled in our center. They were classified into 3 groups according to the image features in mediastinal window detected by computed tomography of nodules: group A (equal to or more than 2 solid-dominant nodules); group B (1 solid-dominant nodule plus other GGO [ground-glass opacity] nodules) and group C (multiple GGO nodules). The clinical characteristic and outcomes were compared among the 3 groups. The epidermal growth factor receptor (EGFR) mutations and the programmed death-ligand 1 (PD-L1) expression was analyzed in a portion of the patients.

      Results

      A total of 297 patients were enrolled, consist of 43 in group A, 112 in s group B and 142 in group C. Compared to patients in group A, patients in group C showed younger age at diagnosis (p < 0.001) and female was more common (p < 0.001). Interestingly, most patients (76.8% vs. 58.1% in group A) in group C were diagnosed with no symptoms and only 15 (10.6%) patients had smoking history (vs. 51.2% in group A, p < 0.001). Importantly, patients in group C showed better respiratory function and lower inflammatory biomarkers. During follow-up, 22 patients had recurrence. The 3-year recurrence-free survival was 100% in group C, 87.1% in group B and 77.6% in group A (p = 0.002). Six patients died, and the 3-year overall survival was 100% in group C, 97.0% in group B and 90.4% in group A (p = 0.002). The positive rate of PD-L1 in 258 detected lesions was 9.7%. A total of 57 patients were tested for PD-L1 in all surgical nodules with the discordance rate of 14%. The positive rate of EGFR gene in 267 detected lesions was 65%. Sixty-eight patients (22.9%) underwent gene detection of all lesions, and the rate of discordance was 54.4%.

      Conclusion

      Although less common, patients in solid nodules group showed more severe clinical characteristics and lower recurrence-free survival and overall survival. The high frequency of EGFR mutationsindicatedpatients with sMPLC might benefit form targeted therapy.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.